Syndax Pharmaceuticals Q3 revenue misses estimates

Syndax Pharmaceuticals

03/11/2025 21:07

Overview

Syndax Q3 revenue grows 21% yr/yr but misses analyst expectations

Adjusted EPS for Q3 beats consensus

Company reports strong demand for Revuforj and Niktimvo, with significant revenue increases

Outlook

Company expects full-year operating expenses of $380 to $385 mln

Syndax anticipates stable operating expenses over the next few years

Company projects cash reserves and revenue to lead to profitability

Result Drivers

REVUFORJ DEMAND - Strong demand for Revuforj evidenced by 25% increase in prescriptions and 12% revenue growth over 2Q25

FDA APPROVAL IMPACT - Recent FDA approval for Revuforj in R/R NPM1m AML boosts demand

NIKTIMVO REVENUE GROWTH - Niktimvo net revenue increased by 27% over 2Q25, supported by co-commercialization with Incyte

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$45.87 mln
$47.97 mln (14 Analysts)
Q3 EPS
Beat
-$0.70
-$0.71 (13 Analysts)
Q3 Net Income
Beat
-$60.71 mln
-$61.84 mln (12 Analysts)
Q3 Cash & Investments
$456.10 mln
Q3 Operating Expenses
$103.29 mln
Q3 Operating Income
-$57.42 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Syndax Pharmaceuticals Inc is $37.50, about 63.5% above its October 31 closing price of $13.70

Press Release: ID:nGNXG3tM5

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)